Clinical Characteristics of the Study Population in Explorative and Biomarker Discovery Phases of the Study
| Characteristic . | Endometriosis (n = 8 Women; 23 Samples) . | Healthy controls,(n = 8 Women; 24 Samples) . | P Value . |
|---|---|---|---|
| Explorative and biomarker discovery phasea | |||
| Age, y (mean ± SD) | 33.4 ± 5.6 | 39.5 ± 4.8 | 0.035 |
| BMI, kg/m2 (mean ± SD) | 26.5 ± 3.3 | 28.3 ± 5.1 | 0.414 |
| Surgical inspection of pelvis, n (%) | 8 (100%) | 3 (37.5%) | |
| Indications for surgery, n (%) | |||
| Pain | 4 (50%) | — | |
| Pain plus infertility | 4 (50%) | — | |
| Sterilization | — | 3 (100%) | |
| Severity of endometriosis (rASRM), n (%) | |||
| Minimal–mild (stage I to II) | 5 (62.5%) | NA | |
| Moderate–severe (stage III to IV) | 3 (37.5%) | NA |
| Characteristic . | Endometriosis (n = 8 Women; 23 Samples) . | Healthy controls,(n = 8 Women; 24 Samples) . | P Value . |
|---|---|---|---|
| Explorative and biomarker discovery phasea | |||
| Age, y (mean ± SD) | 33.4 ± 5.6 | 39.5 ± 4.8 | 0.035 |
| BMI, kg/m2 (mean ± SD) | 26.5 ± 3.3 | 28.3 ± 5.1 | 0.414 |
| Surgical inspection of pelvis, n (%) | 8 (100%) | 3 (37.5%) | |
| Indications for surgery, n (%) | |||
| Pain | 4 (50%) | — | |
| Pain plus infertility | 4 (50%) | — | |
| Sterilization | — | 3 (100%) | |
| Severity of endometriosis (rASRM), n (%) | |||
| Minimal–mild (stage I to II) | 5 (62.5%) | NA | |
| Moderate–severe (stage III to IV) | 3 (37.5%) | NA |
| Characteristic . | Endometriosis (n = 10 Women; 10 Samples) . | Symptomatic Controls (n = 10 Women; 10 Samples) . | P Value . |
|---|---|---|---|
| Biomarker discovery phaseb | |||
| Age, y (mean ± SD) | 32.7 ± 4.7 | 28.1 ± 6.7 | 0.073 |
| BMI, kg/m2 (mean ± SD) | 23.1 ± 2.3 | 26.8 ± 5.02 | 0.05 |
| Stage of menstrual cycle, n (%) | 0.851 | ||
| Early proliferative | 0 (0%) | 2 (20%) | |
| Late proliferative | 1 (10%) | 1 (10%) | |
| Secretory | 8 (80%) | 6 (60%) | |
| Undetermined | 1 (10%) | 1 (10%) | |
| Indications for surgery, n (%) | >0.999 | ||
| Pain | 7 (70%) | 7 (70%) | |
| Pain plus infertility | 3 (30%) | 3 (30%) | |
| Severity of endometriosis (rASRM), n (%) | |||
| Minimal–mild (stage I to II) | 0 (0%) | NA | |
| Moderate–severe (stage III to IV) | 10 (100%) | NA |
| Characteristic . | Endometriosis (n = 10 Women; 10 Samples) . | Symptomatic Controls (n = 10 Women; 10 Samples) . | P Value . |
|---|---|---|---|
| Biomarker discovery phaseb | |||
| Age, y (mean ± SD) | 32.7 ± 4.7 | 28.1 ± 6.7 | 0.073 |
| BMI, kg/m2 (mean ± SD) | 23.1 ± 2.3 | 26.8 ± 5.02 | 0.05 |
| Stage of menstrual cycle, n (%) | 0.851 | ||
| Early proliferative | 0 (0%) | 2 (20%) | |
| Late proliferative | 1 (10%) | 1 (10%) | |
| Secretory | 8 (80%) | 6 (60%) | |
| Undetermined | 1 (10%) | 1 (10%) | |
| Indications for surgery, n (%) | >0.999 | ||
| Pain | 7 (70%) | 7 (70%) | |
| Pain plus infertility | 3 (30%) | 3 (30%) | |
| Severity of endometriosis (rASRM), n (%) | |||
| Minimal–mild (stage I to II) | 0 (0%) | NA | |
| Moderate–severe (stage III to IV) | 10 (100%) | NA |
Clinical Characteristics of the Study Population in Explorative and Biomarker Discovery Phases of the Study
| Characteristic . | Endometriosis (n = 8 Women; 23 Samples) . | Healthy controls,(n = 8 Women; 24 Samples) . | P Value . |
|---|---|---|---|
| Explorative and biomarker discovery phasea | |||
| Age, y (mean ± SD) | 33.4 ± 5.6 | 39.5 ± 4.8 | 0.035 |
| BMI, kg/m2 (mean ± SD) | 26.5 ± 3.3 | 28.3 ± 5.1 | 0.414 |
| Surgical inspection of pelvis, n (%) | 8 (100%) | 3 (37.5%) | |
| Indications for surgery, n (%) | |||
| Pain | 4 (50%) | — | |
| Pain plus infertility | 4 (50%) | — | |
| Sterilization | — | 3 (100%) | |
| Severity of endometriosis (rASRM), n (%) | |||
| Minimal–mild (stage I to II) | 5 (62.5%) | NA | |
| Moderate–severe (stage III to IV) | 3 (37.5%) | NA |
| Characteristic . | Endometriosis (n = 8 Women; 23 Samples) . | Healthy controls,(n = 8 Women; 24 Samples) . | P Value . |
|---|---|---|---|
| Explorative and biomarker discovery phasea | |||
| Age, y (mean ± SD) | 33.4 ± 5.6 | 39.5 ± 4.8 | 0.035 |
| BMI, kg/m2 (mean ± SD) | 26.5 ± 3.3 | 28.3 ± 5.1 | 0.414 |
| Surgical inspection of pelvis, n (%) | 8 (100%) | 3 (37.5%) | |
| Indications for surgery, n (%) | |||
| Pain | 4 (50%) | — | |
| Pain plus infertility | 4 (50%) | — | |
| Sterilization | — | 3 (100%) | |
| Severity of endometriosis (rASRM), n (%) | |||
| Minimal–mild (stage I to II) | 5 (62.5%) | NA | |
| Moderate–severe (stage III to IV) | 3 (37.5%) | NA |
| Characteristic . | Endometriosis (n = 10 Women; 10 Samples) . | Symptomatic Controls (n = 10 Women; 10 Samples) . | P Value . |
|---|---|---|---|
| Biomarker discovery phaseb | |||
| Age, y (mean ± SD) | 32.7 ± 4.7 | 28.1 ± 6.7 | 0.073 |
| BMI, kg/m2 (mean ± SD) | 23.1 ± 2.3 | 26.8 ± 5.02 | 0.05 |
| Stage of menstrual cycle, n (%) | 0.851 | ||
| Early proliferative | 0 (0%) | 2 (20%) | |
| Late proliferative | 1 (10%) | 1 (10%) | |
| Secretory | 8 (80%) | 6 (60%) | |
| Undetermined | 1 (10%) | 1 (10%) | |
| Indications for surgery, n (%) | >0.999 | ||
| Pain | 7 (70%) | 7 (70%) | |
| Pain plus infertility | 3 (30%) | 3 (30%) | |
| Severity of endometriosis (rASRM), n (%) | |||
| Minimal–mild (stage I to II) | 0 (0%) | NA | |
| Moderate–severe (stage III to IV) | 10 (100%) | NA |
| Characteristic . | Endometriosis (n = 10 Women; 10 Samples) . | Symptomatic Controls (n = 10 Women; 10 Samples) . | P Value . |
|---|---|---|---|
| Biomarker discovery phaseb | |||
| Age, y (mean ± SD) | 32.7 ± 4.7 | 28.1 ± 6.7 | 0.073 |
| BMI, kg/m2 (mean ± SD) | 23.1 ± 2.3 | 26.8 ± 5.02 | 0.05 |
| Stage of menstrual cycle, n (%) | 0.851 | ||
| Early proliferative | 0 (0%) | 2 (20%) | |
| Late proliferative | 1 (10%) | 1 (10%) | |
| Secretory | 8 (80%) | 6 (60%) | |
| Undetermined | 1 (10%) | 1 (10%) | |
| Indications for surgery, n (%) | >0.999 | ||
| Pain | 7 (70%) | 7 (70%) | |
| Pain plus infertility | 3 (30%) | 3 (30%) | |
| Severity of endometriosis (rASRM), n (%) | |||
| Minimal–mild (stage I to II) | 0 (0%) | NA | |
| Moderate–severe (stage III to IV) | 10 (100%) | NA |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
